Company profile

Audited by PwC

Novozymes is the world leader in bioinnovation. Our business is industrial enzymes, microorganisms, and biopharmaceutical ingredients. Our biological solutions help companies make more from less, as our solutions save energy and raw materials, and reduce waste. The result is higher quality, lower costs, lower CO2 emissions, and a better environment.

Novozymes is organized into two business areas, each covering a number of industries: Enzyme Business and BioBusiness. The development, production, distribution, and sale of enzymes form the major part of our business, currently accounting for 94% of sales. BioBusiness, accounting for the remaining 6%, is home to both a smaller, established business in microorganisms and biopharmaceutical ingredients and a portfolio of initiatives where Novozymes is exploring business opportunities outside the enzyme sphere.

We generated sales of DKK 9,724 million and EBIT of DKK 2,117 million in 2010.

Rethink Tomorrow

We use biotechnology to discover new sustainable solutions. More than 16% of Novozymes’ global workforce of 5,432 works on innovation and development, and we invest around 14% of our sales in research and development.
Our solutions are based on a unique technology platform that provides a wealth of opportunities for the world’s industries. Gene technology, microbiology, and fermentation technology are some of the tools on which we base our business. Combining industrial insight with this technology platform, we partner with customers across a broad range of industries to create tomorrow’s industrial biosolutions that not only improve the use of our planet’s resources but also our customers’ business. We currently hold more than 6,500 granted or pending patents, which is an indication of the possibilities that emerge when nature and technology join forces.

Sustainability is integrated

Sustainability is an integral part of our business, and we enable our customers to optimize their use of raw materials and energy, thereby reducing the environmental impact of their operations. In 2010 alone, the worldwide application of our products enabled reductions in CO2 emissions of approximately 40 million tons.

We believe in decency and responsibility in business, which includes respect for all stakeholders. Our commitments to international agreements and universal values help define issues and challenges of relevance to our stakeholders and our business:

  • We subscribe to the United Nations Global Compact  
  • We support the United Nations Declaration of Human Rights 
  • We support the United Nations Convention on Biological Diversity
  • We subscribe to the International Chamber of Commerce’s Charter for Sustainable Development
My Report

0 pages added

MyReport Videos
What impression does a first time visitor to Novozymes get of our company? Lifestyle expert Christine Feldthaus takes a closer look.
A lifestyle expert on what characterizes Novozymes
A lifestyle expert on what characterizes Novozymes
How Novozymes rethinks tomorrow
Per Falholt, Research & Development